NASDAQ:ARQL - ArQule Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.74 -0.04 (-1.06 %)
(As of 01/22/2019 07:06 AM ET)
Previous Close$3.78
Today's Range$3.62 - $3.86
52-Week Range$1.46 - $7.21
Volume981,122 shs
Average Volume1.11 million shs
Market Capitalization$407.64 million
P/E Ratio-9.59
Dividend YieldN/A
Beta1.85
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARQL
CUSIP04269E10
Phone781-994-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.71 million
Book Value$0.16 per share

Profitability

Net Income$-29,200,000.00

Miscellaneous

Employees32
Market Cap$407.64 million
OptionableOptionable

ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Wednesday, October, 31st. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company had revenue of $4.98 million for the quarter, compared to analyst estimates of $2.44 million. During the same period in the previous year, the firm posted ($0.09) earnings per share. View ArQule's Earnings History.

When is ArQule's next earnings date?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for ArQule.

What guidance has ArQule issued on next quarter's earnings?

ArQule updated its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of $-0.17--0.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.12. The company issued revenue guidance of $24-25 million, compared to the consensus revenue estimate of $22.66 million.

What price target have analysts set for ARQL?

5 equities research analysts have issued twelve-month price targets for ArQule's shares. Their predictions range from $7.00 to $7.00. On average, they expect ArQule's share price to reach $7.00 in the next year. This suggests a possible upside of 87.2% from the stock's current price. View Analyst Price Targets for ArQule.

What is the consensus analysts' recommendation for ArQule?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.

Has ArQule been receiving favorable news coverage?

News articles about ARQL stock have trended very positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ArQule earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Are investors shorting ArQule?

ArQule saw a decline in short interest in December. As of December 14th, there was short interest totalling 7,751,941 shares, a decline of 17.3% from the November 30th total of 9,378,896 shares. Based on an average daily volume of 1,552,959 shares, the days-to-cover ratio is presently 5.0 days. Approximately 7.9% of the company's shares are short sold. View ArQule's Current Options Chain.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:
  • Mr. Paolo Pucci, CEO & Director (Age 58)
  • Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 56)
  • Mr. Robert J. Weiskopf, CFO & Treasurer (Age 68)
  • Dr. Brian Schwartz, Chief Medical Officer (Age 57)
  • Ms. Dawn Schottlandt, VP of Investor Relations & Corp. Communications

Who are ArQule's major shareholders?

ArQule's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.

Which institutional investors are buying ArQule stock?

ARQL stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Meeder Asset Management Inc.. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.

How do I buy shares of ArQule?

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $3.74.

How big of a company is ArQule?

ArQule has a market capitalization of $407.64 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.

What is ArQule's official website?

The official website for ArQule is http://www.arqule.com.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]


MarketBeat Community Rating for ArQule (NASDAQ ARQL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel